January 7, 2015 /3BL Media/ - SynCardia Systems, Inc. has received FDA approval to conduct a clinical study of the effectiveness of the SynCardia temporary Total Artificial Heart for permanent use, also called destination therapy.
On December 18, 2014, the United States Food and Drug Administration (FDA) approved the SynCardia Investigational Device Exemption (IDE) application to conduct the study in 19 patients who do not qualify for a donor heart transplant.
Read More: http://3blmedia.com/News/FDA-Approves-SynCardia-Total-Artificial-Heart-Destination-Therapy-Study
© 2014 | 3BL Media/SynCardia Systems | All Rights Reserved
